- Home
- SPOK vs IMMP Comparison
SPOK vs IMMP Comparison
Compare SPOK & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- IMMP
- Stock Information
- Founded
- SPOK 2004
- IMMP 1987
- Country
- SPOK United States
- IMMP Australia
- Employees
- SPOK N/A
- IMMP N/A
- Industry
- SPOK Telecommunications Equipment
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- SPOK Telecommunications
- IMMP Health Care
- Exchange
- SPOK Nasdaq
- IMMP Nasdaq
- Market Cap
- SPOK 318.9M
- IMMP 211.1M
- IPO Year
- SPOK 1992
- IMMP N/A
- Fundamental
- Price
- SPOK $16.54
- IMMP $1.86
- Analyst Decision
- SPOK Hold
- IMMP Buy
- Analyst Count
- SPOK 1
- IMMP 2
- Target Price
- SPOK $15.00
- IMMP $8.50
- AVG Volume (30 Days)
- SPOK 180.4K
- IMMP 648.0K
- Earning Date
- SPOK 04-30-2025
- IMMP 05-16-2025
- Dividend Yield
- SPOK 7.54%
- IMMP N/A
- EPS Growth
- SPOK N/A
- IMMP N/A
- EPS
- SPOK 0.77
- IMMP N/A
- Revenue
- SPOK $139,038,000.00
- IMMP $3,019,249.00
- Revenue This Year
- SPOK $2.26
- IMMP $11.25
- Revenue Next Year
- SPOK $0.14
- IMMP $10.22
- P/E Ratio
- SPOK $21.51
- IMMP N/A
- Revenue Growth
- SPOK N/A
- IMMP 24.11
- 52 Week Low
- SPOK $13.55
- IMMP $1.32
- 52 Week High
- SPOK $17.96
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- SPOK 59.93
- IMMP 53.43
- Support Level
- SPOK $13.55
- IMMP $1.44
- Resistance Level
- SPOK $16.60
- IMMP $2.71
- Average True Range (ATR)
- SPOK 0.61
- IMMP 0.17
- MACD
- SPOK 0.21
- IMMP 0.05
- Stochastic Oscillator
- SPOK 95.22
- IMMP 29.75
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.